Esperion EU Partner Reports Final Real-World Results From MILOS German Cohort Demonstrating Strong Increase In LDL-C Goal Achievement With Addition Of Bempedoic Acid
Portfolio Pulse from Benzinga Newsdesk
Esperion's European partner, Daiichi Sankyo Europe, reported positive real-world results from the MILOS study in Germany, showing significant LDL-C reduction with bempedoic acid. The study demonstrated a 7-fold increase in patients achieving LDL-C goals, confirming the drug's effectiveness and safety.
October 02, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion's bempedoic acid demonstrated significant LDL-C reduction in a real-world German study, increasing patient goal achievement 7-fold. The study confirms the drug's effectiveness and safety, potentially boosting investor confidence.
The MILOS study results highlight the effectiveness and safety of Esperion's bempedoic acid, which could lead to increased adoption and sales. The significant LDL-C reduction and safety profile are likely to positively influence investor sentiment and stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90